Molecular Threat of Splicing Factor Mutations to Myeloid Malignancies and Potential Therapeutic Modulations

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Splicing factors are frequently mutated in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
• The precise mechanisms by which these mutations contribute to oncogenesis are not fully elucidated.
• Current therapeutic options for MDS/AML patients with spliceosome mutations are limited.

Purpose of the Study:

• To review recent advancements in understanding the mechanistic role of splicing factor mutations in disease progression.
• To summarize emerging therapeutic strategies for MDS and AML with spliceosome mutations.

Main Methods:

• Literature review of recent mechanistic studies.
• Analysis of ongoing clinical trials for novel therapeutic agents.

Main Results:

• Splicing factor mutations are implicated in the pathogenesis of MDS and AML.
• Targeting strategies include small molecule inhibitors of the spliceosome, DNA damage response, and immune pathways.
• Clinical trials are evaluating the efficacy of these novel approaches.

Conclusions:

• A deeper mechanistic understanding of splicing factor mutations is crucial for developing effective therapies.
• Targeted therapies hold promise for improving clinical outcomes in patients with MDS/AML and spliceosome mutations.